|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-3-3
|
|
pubmed:abstractText |
Neointimal hyperplasia is the first step in a cascade leading to a reduced patency rate of saphenous vein grafts in comparison to arterial grafts in coronary artery bypass grafting. Using cultured human saphenous vein grafts as a model for coronary artery bypass grafting, we investigated if the mammalian target of rapamycin inhibitor everolimus attenuates neointimal hyperplasia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1873-734X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
515-20
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19167904-Blotting, Western,
pubmed-meshheading:19167904-Coronary Artery Bypass,
pubmed-meshheading:19167904-Humans,
pubmed-meshheading:19167904-Hyperplasia,
pubmed-meshheading:19167904-Immunosuppressive Agents,
pubmed-meshheading:19167904-Ki-67 Antigen,
pubmed-meshheading:19167904-Organ Culture Techniques,
pubmed-meshheading:19167904-Ribosomal Protein S6 Kinases,
pubmed-meshheading:19167904-Saphenous Vein,
pubmed-meshheading:19167904-Sirolimus,
pubmed-meshheading:19167904-Tunica Intima,
pubmed-meshheading:19167904-Vascular Patency
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts.
|
|
pubmed:affiliation |
Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria. severin.semsroth@i-med.ac.at
|
|
pubmed:publicationType |
Journal Article
|
